All In Biotech

Drug Trial Radar · NCT04908865

Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients With Active Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

67

Actual

Start

Oct 21, 2021

Primary completion

May 23, 2024

Study completion Aug 13, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to evaluate the safety, efficacy and pharmacokinetics of belimumab administered in combination with background standard therapy in pediatric participants with active SLE.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • BelimumabDrug

    Belimumab will be administered.

  • Standard therapyDrug

    Standard therapy will be continued.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events of Special Interest (AESIs) Through Week 52Time frame: Up to Week 52
  2. Number of Participants With Greater Than Equal to (>=) 4 Points Reduction From Baseline to Week 52 in Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) ScoreTime frame: Baseline (Day 0) and Week 52

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Changchun, China

  • GSK Investigational Site

    Changsha, China

  • GSK Investigational Site

    Chongqing, China

  • GSK Investigational Site

    Hangzhou, China

  • GSK Investigational Site

    Nanjing, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Suzhou, China

  • GSK Investigational Site

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.